Trevi Therapeutics, Inc. (TRVI)

Market Cap	1.70B
Revenue (ttm)	n/a
Net Income (ttm)	-45.86M
Shares Out	128.23M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,476,399
Open	11.48
Previous Close	11.36
Day's Range	11.28 - 13.73
52-Week Range	2.36 - 13.73
Beta	0.84
Analysts	Strong Buy
Price Target	20.59 (+54.93%)
Earnings Date	Nov 13, 2025

About TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in pat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2019
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: TRVI
• Website: https://www.trevitherapeutics.com

Analyst Summary

According to 11 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price target is $20.59, which is an increase of 54.93% from the latest price.

Price Target

$20.59

(54.93% upside)

Analyst Consensus: Strong Buy